The cell and gene therapy (CGT) sector was buzzing as 2024 wrapped up, with fresh approvals and promising clinical trial results having lit the way forward. Mesoblast’s Ryoncil snagged FDA approval in December for pediatric graft-versus-host disease, Adaptimmune’s Tecelra got the green light in August for synovial sarcoma, and Casgevy—the pioneering CRISPR-based therapy—scored its first … Looking Back at the Cell and Gene Therapy Leaders That Made Waves in 2024 Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.